Viz.ai, a US-based healthcare company focused on AI-powered disease detection, has deepened its partnership with Softek Illuminate to improve cerebral aneurysm patient care.
Softek Illuminate develops unique natural language processing (NLP) and AI software to identify at-risk patients, evaluate disease severity and facilitate disease surveillance.
The expanded partnership aims to improve the detection and monitoring of cerebral aneurysm patients, enable timely interventions and ensure patients are not lost to follow-up.
Viz.ai will leverage its Viz Aneurysm and Softek Illuminate its Discovery360 to provide care teams with insights that ensure timely diagnosis and patient follow-up.
Viz.ai chief product and marketing officer Jieun Choe said: “An estimated 6.7 million people in the United States have an unruptured brain aneurysm.
“Through our collaboration with Illuminate, we have the opportunity to detect and monitor aneurysms more effectively by using AI-powered tools that prevent patients from falling through the cracks.
“We are confident this collaboration will help more patients get the continuity of care and treatment they need to reduce aneurysm rupture.”
According to the Brain Aneurysm Foundation, around 30,000 people in the US suffer a brain aneurysm rupture annually, with half of these cases proving fatal.
Viz Aneurysm, an AI-powered tool, analyses computed tomography angiograms (CTAs) to detect suspected cerebral aneurysms and simplifies referrals.
Illuminate’s Discovery360 complements the AI tool by identifying and tracking patients.
Softek Illuminate’s Discovery360 technology will use people, process, and technology to identify and monitor lost aneurysm patients.
In a recent clinical trial conducted across eight stroke centres, nearly 1,200 CTAs were screened for stroke evaluation.
In the study, Viz Aneurysm helped determine that 85% of aneurysms had not been previously referred to neurology for follow-up, said Viz.ai.
Recently, Viz.ai has partnered with precision oncology company Guardant Health to help oncologists diagnose lung cancer earlier and improve patient outcomes.
Illuminate CEO Cole Erdmann said: “We are pleased to partner with Viz.ai to provide an end-to-end workflow, including follow-up surveillance and disease management, by combining our best-in-class technologies.
“This will ensure patients and physicians are able to make the best care decisions ultimately preventing ruptures.”
